Multi-arm Phase 2 Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer
Latest Information Update: 31 Jan 2025
Price :
$35 *
At a glance
- Drugs Ubamatamab (Primary) ; Bevacizumab; Cemiplimab; Doxorubicin liposomal; Fianlimab; Sarilumab
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 31 Jan 2025 New trial record